Teijin Pharma

Teijin Pharma is the healthcare division of the Japanese conglomerate Teijin Limited, focusing on the development of innovative pharmaceuticals and home healthcare solutions. The company maintains a strong market position in Japan, particularly in the fields of bone and joint diseases, respiratory medicine, and metabolic disorders. Its flagship product, Feburic (febuxostat), is a globally recognized treatment for gout and hyperuricemia. Teijin Pharma is unique in its integration of pharmaceutical products with medical devices, providing comprehensive services such as home oxygen therapy and CPAP for sleep apnea. The company continues to expand its pipeline through internal R&D and strategic global partnerships to address unmet medical needs in chronic and orphan diseases.